Clinical Trial

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2023 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-22.
Status change: Not Yet Recruiting → Recruiting 2023-04-12
Trial Details
NCT Number NCT05754853
Lead Sponsor Shanghai Miracogen Inc.
Conditions Advanced or Metastatic Urothelium Cancer
Enrollment 290 participants
Start Date 2023-04-06
Primary Completion 2025-10 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2023-04-13